8-K: Lumexa Imaging Reports Q2 Growth, Narrowed EBITDA Guidance

Lumexa Imaging announced second quarter 2026 results, showing increased revenues and a return to net income, while updating its full-year outlook.

Summary

• Lumexa Imaging reported consolidated revenues of $264.2 million for Q2 2026, a 5.1% increase from $251.4 million in Q2 2025.
• System-wide revenue grew by 6.0%, with consolidated advanced outpatient volume up 6.8% and system-wide up 6.3%.
• The company achieved net income of $2.7 million in Q2 2026, a significant improvement from a net loss of $7.2 million in Q2 2025.
• Adjusted EBITDA was $56.4 million, a slight increase from $56.3 million in the prior year, though the Adjusted EBITDA margin decreased to 21.4% from 22.4%.
• Full-year 2026 consolidated revenue guidance remains $1.045 billion to $1.097 billion.
• Full-year 2026 Adjusted EBITDA guidance was narrowed to $235 million to $241 million, with an unchanged midpoint of $238 million.
• Adjusted EPS guidance for the full year is reiterated at $0.71 to $0.77 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with revenue growth and a significant swing from net loss to net income, though Adjusted EBITDA margin slightly decreased.

Positives

• Consolidated revenues increased by 5.1% to $264.2 million in Q2 2026.
• System-wide revenue growth of 6.0% indicates broader operational expansion.
• A significant swing from a net loss of $7.2 million in Q2 2025 to a net income of $2.7 million in Q2 2026.
• Consolidated advanced outpatient volume grew by 6.8%, demonstrating increased utilization of higher-value services.
• Same-center advanced outpatient volume growth of 5.2% (consolidated) and 4.9% (system-wide) suggests organic growth within existing facilities.
• Announced four new imaging centers year-to-date and a joint venture with Hospital for Special Surgery (HSS), marking the ninth health system partnership.
• Cash and cash equivalents increased to $69.7 million from $58.8 million at the end of 2025.

Negatives

• Adjusted EBITDA margin decreased to 21.4% in Q2 2026 from 22.4% in Q2 2025.
• The full-year Adjusted EBITDA guidance range was narrowed, which could imply less certainty in future performance, although the midpoint is unchanged.
• The company noted approximately $7 million of public company costs not incurred in 2025, which lowers the reported Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4% at the midpoint.

Risks

• The company's future results are subject to risks and uncertainties that could cause actual results to differ materially from projections, as detailed in its Form 10-K and subsequent 10-Q filings.
• Potential variability of reconciling items for non-GAAP measures, such as transaction costs and severance, could significantly impact future results.

Future Outlook

The company reiterates its full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion. Full-year 2026 Adjusted EBITDA guidance is narrowed to $235 million to $241 million, with the midpoint unchanged at $238 million. Guidance for Adjusted EPS remains $0.71 to $0.77 per share.

Management Comments

• "During the second quarter, we continued to build on our momentum, delivering strong same-center growth, expanding our mix of advanced imaging and ramping new centers," said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging.
• "Some highlights include announcing four new imaging centers year to date and a joint venture with Hospital for Special Surgery (HSS), a globally recognized leader in musculoskeletal health, marking our ninth health system partnership and our second new joint venture in the past twelve months."
• "With a large and growing addressable market and durable demand tailwinds, we believe Lumexa Imaging is well positioned to deliver sustained, profitable growth while expanding access to high-quality, lower-cost imaging for patients, providers, and payors."

Industry Context

StockSavvy.ai notes that Lumexa Imaging's performance aligns with broader trends in the outpatient imaging sector, which benefits from an aging population, increased demand for specialized diagnostics, and a shift towards lower-cost outpatient settings. The company's strategic partnerships with health systems, like the one with HSS, are a common strategy to enhance market access and service offerings.

Related Party Transactions

• Accounts receivable, related party: $20,024 thousand as of June 30, 2026, compared to $18,893 thousand as of December 31, 2025.

Stakeholder Impact

• Shareholders: Positive impact from improved net income and reiterated revenue/adjusted EPS guidance, though a slight dip in Adjusted EBITDA margin may warrant monitoring.
• Patients: Continued expansion of access to high-quality, lower-cost imaging services.
• Providers and Payors: Strengthened partnerships with health systems like HSS, indicating a collaborative approach to care delivery.

Next Steps

• Continue to build on momentum with strong same-center growth.
• Expand mix of advanced imaging services.
• Ramp new imaging centers.
• Host conference call and webcast on August 12, 2026, at 5:00 p.m. ET to discuss results and outlook.

Key Dates

Recommendation

The company shows solid revenue growth and a significant improvement in net income, alongside reiterated full-year guidance for revenue and adjusted EPS. However, the slight decrease in Adjusted EBITDA margin and the inclusion of public company costs impacting growth metrics suggest a need for cautious optimism. A 'hold' recommendation reflects the positive operational trends balanced against margin pressures and the ongoing integration of new centers and partnerships.

Keywords

outpatient imaging, financial results, revenue growth, Adjusted EBITDA, joint venture, health system partnership, advanced imaging, same-center growth